Research Article

Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study

Table 2

C.E.R.A. administration (safety population, ).

Reason for initiation of C.E.R.A., (%)a
 New and innovative application scheme173 (62.2)
 No previous ESA therapy86 (30.9)
 Therapeutic failure of previously used ESA16 (5.8)
 Adverse effects of previously used ESA2 (0.7)
 Other5 (1.8)
Route of application, (%)
 Subcutaneous260 (93.2)
 Subcutaneous and intravenous 3 (1.1)
 Unknown16 (5.7)
Application by, (%)
 Patient180 (64.5)
 Patient or nurse1 (0.4)
 Physician28 (10.0)
 Physician or patient69 (24.7)
 Physician or patient or nurse1 (0.4)
C.E.R.A. dose per application, µg
 Initial dose
  Mean (SD)92.2 (56.0)
  Median (range)75.0 (30–360)
 Final dose, mean (SD)
  Mean (SD)98.8 (59.5)
  Median (range)75.0 (30–360)
 Throughout study
  Mean (SD)95.1 (53.2)
  Median (range)76.9 (30–360)
Time between C.E.R.A. applications, days
 Mean (SD)34.0 (11.9)
 Median (range)31.2 (13–91)
C.E.R.A. dose changes, (%)
 No dose change119 (42.7)
 Any dose change160 (57.3)
 Any dose decrease 117 (41.9)
 Any dose increase 132 (47.3)

C.E.R.A.: continuous erythropoietin receptor activator; SD: standard deviation.
aMore than one reason could be selected from a preprinted list.